i 1.00 Hours

Course Overview

Botulinum toxin is derived from the bacterium Clostridium botulinum. It was first discovered in the 19th century as a toxin causing “sausage poisoning” and evolved into use as a medical treatment for conditions caused by muscle overactivity. It works by inhibiting the release of acetylcholine at the neuromuscular junction, which causes muscle weakness and paralysis. Four types of botulinum toxin preparations are currently available for clinical use. Indications for the various products include treatment of strabismus, blepharospasm, cervical dystonia, spasticity, hyperhidrosis, sialorrhea, migraine, and overactive bladder, and for aesthetic medicine. Botulinum toxin is also being studied in the treatment of various types of pain such as fibromyalgia and neuropathic pain.

About the Course Author

Melanie K. Padgett, PharmD received her doctor of pharmacy from Duquesne University Mylan School of Pharmacy in 2011. Melanie K Padgett, PharmD has declared that no conflict of interest, Relevant Financial Relationship or Relevant Non-Financial Relationship exists.

Get started now and your first course is free!

Become a member today and enjoy instant savings on all courses

Accreditation Information

Certificates provided by accrediting body (1 Match)

  • Accreditation Council for Pharmacy Education


    In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Type Activity: Knowledge
    Target Audience Designation: P
    ACPE Universal Activity Number: JA4008266-0000-21-019-H01-P

Course Details
  • Course Code:

  • Hours:

  • Type:

    Online Course
  • Release Date:

  • Expiration Date:

  • Learning Objectives:

    Discuss the history of botulinum toxin and its evolution from poison to medical modality.; Identify the indications and dosing of currently approved botulinum toxin preparations.; Recognize adverse effects and precautions for the use of botulinum toxin.
  • Target Audience:

    The target audience for this course is: Pharmacists; in the following settings: Acute Care Facility.
  • Course Delivery Method and Format:

    Asynchronous/Online Distance Learning; please see certificate details for specifics on delivery format.
    Relias has a grievance policy in place to facilitate reports of dissatisfaction. Relias will make every effort to resolve each grievance in a mutually satisfactory manner. In order to report a complaint or grievance please contact Relias.
    If you require special accommodations to complete this module, please contact Relias Support by completing the web form (https://www.relias.com/help) or by using the chat functionality.
    All courses offered by Relias, LLC are developed from a foundation of diversity, inclusiveness, and a multicultural perspective. Knowledge, values and awareness related to cultural competency are infused throughout the course content.
    Reference herein to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer or otherwise does not constitute or imply any endorsement, recommendation, or favoring of, or affiliation with, Relias, LLC.
    All characteristics and organizations referenced in the following training are fictional. Any resemblance to any actual organizations or persons living or dead, is purely coincidental.
    To earn continuing education credit for this course you must achieve a passing score of 80% on the post-test and complete the course evaluation.
  • Accommodations:

    If you require special accommodations to complete this module, please contact Relias Customer Support here.
  • Disclosures:

    Expert Reviewers, Instructors, and Staff Writers disclosures will be listed above after the individuals' biographical paragraph. All other members involved within the planning of this educational activity have declared no conflict of interest exists when planning and developing this course.